Garth William Rapeport

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5169900/publications.pdf

Version: 2024-02-01

52 papers 2,005 citations

331259 21 h-index 315357 38 g-index

54 all docs

54 docs citations

54 times ranked 1682 citing authors

#	Article	IF	CITATIONS
1	Neuropharmacology of emesis induced by anti-cancer therapy. Trends in Pharmacological Sciences, 1988, 9, 334-341.	4.0	319
2	Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults. Nature Medicine, 2022, 28, 1031-1041.	15.2	281
3	Combining fMRI with a Pharmacokinetic Model to Determine Which Brain Areas Activated by Painful Stimulation Are Specifically Modulated by Remifentanil. Neurolmage, 2002, 16, 999-1014.	2.1	175
4	A pharmacokinetic study of granisetron (BRL 43694A), a selective 5-HT3 receptor antagonist: correlation with anti-emetic response. Cancer Chemotherapy and Pharmacology, 1989, 24, 45-9.	1.1	144
5	Clinical Pharmacokinetics of Allopurinol. Clinical Pharmacokinetics, 1986, 11, 343-353.	1.6	109
6	Enzyme-Induction Dependent Bioactivation of Troglitazone and Troglitazone Quinone In Vivo. Chemical Research in Toxicology, 2001, 14, 965-974.	1.7	107
7	Reduced Nasal Viral Load and IFN Responses in Infants with Respiratory Syncytial Virus Bronchiolitis and Respiratory Failure. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1074-1084.	2.5	73
8	The influence of diet upon liver function tests and serum lipids in healthy male volunteers resident in a Phase I unit. British Journal of Clinical Pharmacology, 2003, 57, 199-208.	1.1	72
9	<i>In Vitro</i> and <i>In Vivo</i> Antifungal Profile of a Novel and Long-Acting Inhaled Azole, PC945, on Aspergillus fumigatus Infection. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	60
10	The serotonin type 3 receptor antagonist BRL 43694 and nausea and vomiting induced by cisplatin BMJ: British Medical Journal, 1988, 297, 110-111.	2.4	57
11	Pharmacokinetics and anti-emetic efficacy of BRL43694, a new selective 5HT-3 antagonist. British Journal of Cancer, 1988, 58, 651-653.	2.9	52
12	Current approaches to the discovery of novel inhaled medicines. Drug Discovery Today, 2018, 23, 1705-1717.	3.2	48
13	SARS-CoV-2 Human Challenge Studies â€" Establishing the Model during an Evolving Pandemic. New England Journal of Medicine, 2021, 385, 961-964.	13.9	39
14	Safety and nonclinical and clinical pharmacokinetics of PC945, a novel inhaled triazole antifungal agent. Pharmacology Research and Perspectives, 2021, 9, e00690.	1.1	38
15	CARBAMAZEPINE-INDUCED NON-HEREDITARY ACUTE PORPHYRIA. Lancet, The, 1983, 321, 790-792.	6.3	35
16	Preclinical Characterization of PC786, an Inhaled Small-Molecule Respiratory Syncytial Virus L Protein Polymerase Inhibitor. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	30
17	In vitro antifungal activity of a novel topical triazole PC945 against emerging yeast Candida auris. Journal of Antimicrobial Chemotherapy, 2019, 74, 2943-2949.	1.3	30
18	Nasosorption as a Minimally Invasive Sampling Procedure: Mucosal Viral Load and Inflammation in Primary RSV Bronchiolitis. Journal of Infectious Diseases, 2017, 215, 1240-1244.	1.9	29

#	Article	IF	CITATIONS
19	Antifungal synergy of a topical triazole, PC945, with a systemic triazole against respiratory Aspergillus fumigatus infection. Scientific Reports, 2019, 9, 9482.	1.6	29
20	<i>In Vitro</i> and <i>In Vivo</i> Efficacy of a Novel and Long-Acting Fungicidal Azole, PC1244, on Aspergillus fumigatus Infection. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	24
21	Late therapeutic intervention with a respiratory syncytial virus Lâ€protein polymerase inhibitor, PC786, on respiratory syncytial virus infection in human airway epithelium. British Journal of Pharmacology, 2018, 175, 2520-2534.	2.7	23
22	The role of antifungals in the management of patients with severe asthma. Clinical and Translational Allergy, 2020, 10, 46.	1.4	22
23	Safety and Antiviral Effects of Nebulized PC786 in a Respiratory Syncytial Virus Challenge Study. Journal of Infectious Diseases, 2022, 225, 2087-2096.	1.9	21
24	Clinical Pharmacokinetics of Bretylium. Clinical Pharmacokinetics, 1985, 10, 248-256.	1.6	19
25	Discovery of Narrow Spectrum Kinase Inhibitors: New Therapeutic Agents for the Treatment of COPD and Steroid-Resistant Asthma. Journal of Medicinal Chemistry, 2016, 59, 1727-1746.	2.9	19
26	<i>In Vivo</i> Biomarker Analysis of the Effects of Intranasally Dosed PC945, a Novel Antifungal Triazole, on Aspergillus fumigatus Infection in Immunocompromised Mice. Antimicrobial Agents and Chemotherapy, 2017, 61 , .	1.4	19
27	A Pandemic Lesson for Global Lung Diseases: Exacerbations Are Preventable. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1271-1280.	2.5	19
28	Factors Influencing the Relationship Between Carbamazepine Plasma Concentration and Its Clinical Effects in Patients with Epilepsy. Clinical Neuropharmacology, 1985, 8, 141-149.	0.2	17
29	Discovery of novel benzothienoazepine derivatives as potent inhibitors of respiratory syncytial virus. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 2201-2206.	1.0	15
30	Anti-fungal activity of a novel triazole, PC1244, against emerging azole-resistant Aspergillus fumigatus and other species of Aspergillus. Journal of Antimicrobial Chemotherapy, 2019, 74, 2950-2958.	1.3	12
31	Pseudomonas aeruginosa induces p38MAP kinase-dependent IL-6 and CXCL8 release from bronchial epithelial cells via a Syk kinase pathway. PLoS ONE, 2021, 16, e0246050.	1.1	9
32	Effects of intranasally dosed posaconazole on fungal load and biomarkers in <i>Aspergillus fumigatus</i> infected immunocompromised mice. Mycoses, 2017, 60, 728-735.	1.8	4
33	1335. Safety and Pharmacokinetic Profile of PC786, a Novel Inhibitor of Respiratory Syncytial Virus L-protein Polymerase, in a Single and Multiple-Ascending Dose Study in Healthy Volunteer and Mild Asthmatics. Open Forum Infectious Diseases, 2018, 5, S407-S408.	0.4	4
34	Carbamazepine and Haem Biosynthesis in Man. Clinical Science, 1982, 63, 22P-23P.	1.8	3
35	Loop Diuretics - Infusion or Bolus?. Clinical Science, 1982, 63, 33P-34P.	1.8	1
36	Variability of Phenytoin Protein Binding in Epilepsy. Archives of Neurology, 1984, 41, 363-363.	4.9	1

#	Article	IF	CITATIONS
37	An FMRI method to determine specific drug-induced modulations of functional activations using a pharmacokinetic model. NeuroImage, 2001, 13, 959.	2.1	1
38	Superior Effects Of RV568, A Novel Narrow Spectrum Kinase Inhibitor, To BIRB796, A P38MAPK Inhibitor, On Pro-Inflammatory Cytokine Roduction In Macrophages. , 2011, , .		1
39	Anti-Viral Activities of PC786, a Novel Inhibitor of Respiratory Syncytial Virus L-Protein Polymerase. Open Forum Infectious Diseases, 2016, 3, .	0.4	1
40	Involvement Of P38MAPK Gamma On Corticosteroid Refractory Airway Inflammation Induced By Tobacco Smoke In Mice., 2010,,.		0
41	89 Superior effects of RV568, a narrow spectrum kinase inhibitor, on RSV infection in primary bronchial epithelial cells obtained from patients with cystic fibrosis. Journal of Cystic Fibrosis, 2011, 10, S23.	0.3	O
42	90 Inhibitory effects of RV1088, a novel narrow spectrum kinase inhibitor, on RSV infection in primary bronchial epithelial cells obtained from patients with cystic fibrosis. Journal of Cystic Fibrosis, 2011, 10, S23.	0.3	0
43	Vitamin D And Narrow Spectrum Kinase Inhibitors Modulate Inflammatory Mediator Release In A Model Of Steroid-Insensitivity And Viral Exposure. , $2011, , .$		O
44	Effects Of RV1088, A Narrow Spectrum Kinase Inhibitor, On Human Rhinovirus Replication And Cytokine Production. , $2011, \ldots$		O
45	Superior Effects Of RV1088, A Novel Narrow Spectrum Kinase Inhibitor, To BIRB796, A P38MAPK Inhibitor, On Pro-Inflammatory Cytokine Production In Macrophages., 2011,,.		O
46	Rhinovirus 16 (RV16) Induces Airway Hyper-Responsiveness And Release Of IL-8 And IP-10 From Human Small Airways, Which Is Modulated By Narrow Spectrum Kinase Inhibitors. , 2011, , .		0
47	Effects Of RV568, A Narrow Spectrum Kinase Inhibitor, On Human Rhinovirus Replication And Cytokine Production., 2011,,.		O
48	RV1088, A Narrow Spectrum Kinase Inhibitor, Inhibits Steroid Resistant Viral Exacerbations Of Ovalbumin-Induced Allergic Airways Responses In Guinea-Pigs. , 2011, , .		0
49	Inhibition Of Steroid Resistant Viral Exacerbations Of Ovalbumin-Induced Allergic Airways Responses In Guinea-Pigs By A Narrow Spectrum Kinase Inhibitor, RV568. , 2011, , .		O
50	In Vivo Biomarker Analysis of Intranasally Dosed PC945, a Novel Antifungal Agent, in Aspergillus Fumigatus Infection in Immunocompromised Mice. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
51	G37(P) Laboratory correlates of severity in acute bronchiolitis of infancy. , 2018, , .		O
52	LATE-BREAKING ABSTRACT: Effects of a single treatment with PC786, a novel inhibitor of respiratory syncytial virus replication, on viral load and biomarkers in fully differentiated human bronchial epithelial cells. , 2016, , .		0